Lv1
40 积分 2021-03-22 加入
Treatment of NSCLC after chemoimmunotherapy - are we making headway?
1个月前
已完结
The Nonclinical Safety Assessment of a Novel Anti-CEACAM5 Antibody Exatecan Conjugate Predicts a Low Risk for Interstitial Lung Disease (ILD) in Patients—The Putative Mechanism Behind ILD
6个月前
已完结
The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the N Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer
7个月前
已完结
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
8个月前
已完结
Why PD-L1 expression varies between studies of lung cancer: results from a Bayesian meta-analysis
8个月前
已完结
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
9个月前
已完结
RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future
10个月前
已完结
[Expert consensus on the diagnosis and treatment of anticancer drug-induced interstitial lung disease]
10个月前
已完结
Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody‐drug conjugates–induced interstitial lung disease/pneumonitis: An expert consensus in China
10个月前
已完结
Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline
11个月前
已完结
皖公网安备34019202002308
